Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 9/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26017343 | 0.90 | HRH1 (0.45) | ENPP2HRH1HTR6KDM4EALDH1A1 | |
| SCHEMBL17486943 | 0.80 | ENPP2 (0.61) | ENPP2 | |
| SCHEMBL19271273 | 0.80 | DDB1 (0.46) | ENPP2HRH1HTR6KDM4EALDH1A1 | |
| SCHEMBL13663408 | 0.79 | ENPP2 (0.51) | ENPP2 | |
| SCHEMBL13654578 | 0.78 | ENPP2 (0.45) | ENPP2HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL14995623 | 0.76 | HDAC6 (0.72) | ENPP2HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL17486946 | 0.76 | HDAC1 (0.38) | ENPP2HTR6HDAC1HDAC6KDM4E | |
| SCHEMBL24101726 | 0.76 | CYP1A2 (0.44) | ENPP2HRH1HTR6 | |
| SCHEMBL30339398 | 0.76 | CYP1A2 (0.44) | ENPP2HRH1HTR6 | |
| SCHEMBL17486947 | 0.74 | ENPP2 (0.60) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862721-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-9353113-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-31 | — | — | US | disclosed |
| US-20160031884-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031884-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ENPP2 1/4885HRH1 1854/4885HTR6 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.